Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies
Major Deal For ‘Gene Traffic Control’ Company
Executive Summary
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.
You may also be interested in...
Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.
10 Non-COVID News Updates To Listen For In Second Quarter Reporting
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available Buy Reports
Need a specific report? 1000+ reports available Buy Reports